[1] R.J. Stark, K. Ravishankar,.C. Siow, S. Lee, R. Pepperle, S. Wang, Chronic migraine and chronic daily headache in the Asia-Pacific region: a systematic review, Cephalalgia. 33 (2012) 266–283. doi:10.1177/0333102412468677.
[2] M. Vincent, S. Wang, Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition, Cephalalgia. 38 (2018) 1–211. doi:10.1177/0333102417738202.
[3] M. Linde, M. Wm, C. Ep, M. Dc, Valproate (valproic acid or sodium valproate for the prophylaxis of episodic migraine in adults, Cochrane Database Syst. Rev. (2016). doi:10.1002/14651858.CD010608.Memantine.cochranelibrary.com.
[4] F. Bill, M.G. Foundation, Global, regional, and national burden of migraine and tension-type headache, 1990 – 2016 : a systematic analysis for the Global Burden of Disease Study 2016, Lancet Neurol. 17 (2018) 954–976. doi:10.1016/S1474-4422(18)30322-3.
[5] P.J. Goadsby, P.R. Holland, M. Martins-oliveira, J. Hoffmann, C. Schankin, S. Akerman, Pathophysiology of migraine: a disorder of sensory processing clinical manifestations neural basis of migraine triggers, Physiol. Rev. 97 (2019) 553–622. doi:10.1152/physrev.00034.2015.
[6] M. Bigal, A. Rapoport, F. Sheftell, D. Tepper, Memantine in the preventive treatment of refractory migraine, Headache. 48 (2008) 1337–1342. doi:10.1111/j.1526-4610.2008.01083.x.
[7] R. Noruzzadeh, A. Modabbernia, V. Aghamollaii, M. Ghaffarpour, M. Harirchian, S. Salahi, N. Nikbakht, N. Noruzi, A. Tafakhori, Memantine for prophylactic treatment of migraine without aura- a randomized double-blind placebo-controlled study.pdf, Headache. 56 (2015) 95–103. doi:10.1111/head.12732.
[8] J.C. Rau, D. Dodick, Other Preventive Anti-Migraine Treatments: ACE Inhibitors, ARBs, Calcium Channel Blockers, Serotonin Antagonists, and NMDA Receptor Antagonists, Curr. Treat. Options Neurol. 21 (2019) 17. doi:10.1007/s11940-019-0559-0.
[9] S. Silberstein, P. Tfelt-Hansen, D.MEMANTINE. Dodick, V. Limmroth, R.B. Lipton, J. Pascual, S.J. Wang, Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults, Cephalalgia. 28 (2008) 484–495. doi:10.1111/j.1468-2982.2008.01555.x.
[10] D.F. Stroup, Meta-analysis of observational studies in epidemiology: a proposal for reporting, J. Am. Med. Assoc. 283 (2003) 2008. doi:10.1001/jama.283.15.2008.
[11] D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, T.P. Group, Preferred Reporting Items for Systematic Reviews and Meta-Analyses : The PRISMA Statement, PLoS Med. 6 (2009) e1000097. doi:10.1371/journal.pmed.1000097.
[12] Committee of the International Headache Society., Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain, Cephalalgia. 24 (2004) 1–160.
[13] M. Murad, S. Sultan, S. Haffar, F. Bazerbachi, Methodological quality and synthesis of case series and case reports, Evid. Based. Med. 23 (2018) 60–63. doi:10.1136/bmjebm-2017-110853.
[14] A. Charles, C. Flippen, M.R. Reyes, K.C. Brennan, Memantine for prevention of migraine: a retrospective study of 60 cases, J. Headache Pain. 8 (2007) 248–250. doi:10.1007/s10194-007-0406-7.
[15] F. Assarzadegan, M. Sistanizad, Tolerability and efficacy of Memantine as add on therapy in patients with migraine, Iran. J. Pharm. Res. 16 (2017) 791–797.
[16] S. Shanmugam, K. Karunaikadal, S. Varadarajan, M. Krishnan, Memantine ameliorates migraine headache, Ann. Indian Acad. Neurol. 22 (2019) 286–290. doi:10.4103/aian.AIAN.
[17] S.D. Silberstein, S. Holland, F. Freitag, D. Dodick, C. Argoff, E. Ashman, Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults, Neurology. 78 (2012) 1337–1345. doi:10.1212/wnl.0b013e3182535d20.
[18] M.R. Farlow, S.M. Graham, G. Alva, Memantine for the treatment of Alzheimer’s disease: tolerability and safety data from clinical trials, Drug Saf. 31 (2008) 577–585. doi:10.2165/00002018-200831070-00003.
[19] A. Vgontzas, R. Burch, Episodic migraine with and without aura: key differences and implications for pathophysiology, management, and assessing risks, Curr. Pain Headache Rep. 22 (2018) 28. doi:10.1007/s11916-018-0735-z.